Editorial
merging evidence has pointed to the importance of long noncoding RNAs (lncRNAs) in biological function and disease. However, lncRNAs remain largely unexploited in the vascular system. In this issue of ATVB, Zhao et al 1 identified a novel vascular smooth muscle cell-specific lncRNA, Myoslid. The investigators demonstrated that Myoslid, whose expression is transcriptionally controlled by serum response factor and myocardin (MYOCD), regulates smooth muscle cell proliferation and differentiation program, at least in part, by modulating the transforming growth factor (TGF)-β pathway. This study has uncovered the involvement of noncoding RNAs in the already complicated gene regulatory networks in vascular biology, highlighting the potential of lncRNAs as novel therapeutic targets for cardiovascular disorders.
See accompanying article on page 2088
Cardiovascular disease remains the leading cause of mortality and morbidity worldwide. Over the past decades, intense studies on key molecules that control gene expression (transcription factors and epigenetic regulators) and signaling pathways (eg, the TGF-β, Notch, Hippo pathways) have led to a fundamental understanding of the regulatory mechanisms for cell proliferation, differentiation, migration, and apoptosis in the cardiovascular system, resulting in the identification of potential therapeutic targets for cardiovascular diseases. Despite these advances, a deeper understanding of the intricate layers of gene regulation and molecular mechanisms by which the activity of the aforementioned pathways is regulated is necessary as a means toward precision medicine.
It is now recognized that the majority of our genome is actively transcribed to produce thousands of noncoding transcripts. In particular, lncRNAs, RNAs longer than 200 nucleotides in length, are widely expressed and participate in a variety of biological processes. In recent years, gene expression profiling, thanks to the increased depth of RNA sequencing, has documented that thousands of lncRNAs are expressed in normal and diseased hearts. 2 Several pioneering studies have linked the function of lncRNAs to the maintenance of cardiomyocyte fate (Braveheart) 3, 4 and cardioprotection in response to stress (Myheart). 5, 6 Another study demonstrated that lincRNA-p21 controls cell proliferation and the pathological development of atherosclerosis. 7 Mechanistically, lncRNAs are found in both the nucleus and cytoplasm and have been suggested to regulate transcription and translation. However, the biological functions of most lncRNAs in the cardiovascular system remain largely unexplored.
Transcriptional control plays a vital role in smooth muscle gene expression and vascular function. Myocardin was initially identified as a master regulator of the smooth muscle gene program. 8 Acting as a tissue-specific cofactor of serum response factor, myocardin was shown to transactivate a battery of key smooth muscle genes. 9, 10 In this study, Zhao et al 1 asked whether myocardin could regulate the expression of lncRNA genes in contractile vascular smooth muscle. As expected, on profiling lncRNA expression in human coronary artery smooth muscle cells overexpressing myocardin, they identified 137 lncRNAs whose expression was significantly altered. Among them, Myoslid stood out as a novel, smooth muscle-specific lncRNA. They showed that the expression of Myoslid is transcriptionally regulated by serum response factor and Myocardin. Myoslid seems to be a cytosolic lncRNA, and its expression level is modest when compared with that of protein-coding genes. Overexpression and knockdown experiments indicated that Myoslid participates in the TGF-β signaling pathway to control vascular smooth muscle cell (VSMC) differentiation. 1 Although much is known about the signaling and transcriptional control in the cardiovascular system, there is comparatively less information on the function of lncRNAs and their placement in the vascular gene regulatory network. Myoslid is a new member of the vascular lncRNA pool that regulates cytoskeleton assembly and VSMC differentiation through its activation of contractile gene expression and concomitant suppression of VSMC proliferation and migration. Accordingly, maintenance of Myoslid expression in differentiated VSMCs seems to be essential as its downregulation correlates with the pathological dedifferentiation of smooth muscle. Although Myoslid expression is not sufficient to induce differentiation, it plays a critical function in this process by modulating the activities of MRTFs (myocardin-related transcription factors), and through feedback regulation of both the serum response factor/ Myocd and TGF-β pathways to maintain the differentiated state (Figure) .
In their study, the investigators used both overexpression and siRNA-based knockdown to uncover the function of Myoslid in VSMC in vitro. It will be important to define the in vivo function of this lncRNA, using gain-of-function and loss-of-function approaches in animal models. Ultimately, it will be essential to determine the role of human Myoslid in cardiovascular diseases. Although this report focused on Myoslid, the authors of this study identified over one hundred myocardin-induced lncRNAs. Given the central role of myocardin in smooth muscle differentiation, it would be important to determine whether any of the other lncRNAs identified here also play a role in VSMCs. For example, do any of these lncRNAs modulate the TGF-β pathway? If not, then what smooth muscle pathways do these lncRNAs regulate? And, how many of these are smooth muscle specific? Given recent reports demonstrating that some previously annotated lncRNAs encode micropeptides, 11, 12 the possibility of Myoslid encoding a micropeptide also needs to be formally excluded. In addition, the molecular mechanisms underlying Myoslid function remain to be fully understood. lncRNAs regulate gene expression through various mechanisms: recruitment of chromatin modifiers or transcriptional regulators in cis or in trans, or as molecular sponges by binding to and titrating endogenous mRNAs or miRNAs. Although the authors suggest that Myoslid lacks known miRNA seed sequences to function as a molecular sponge, its cytoplasmic enrichment strongly suggests this mode action to regulate MYOCD-related transcription factor A nucleocytoplasmic shuttling. It is equally attractive to test the hypothesis that Myoslid itself shuttles between nucleus and cytoplasm under pathophysiological conditions. Finally, whether Myoslid, and probably other myocardininduced lncRNAs, is directly involved in human cardiovascular disease is an important link to determine in the future.
